Bajaj Healthcare Ltd
BAJAJHCAREBajaj Healthcare Ltd
BAJAJHCAREPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-79.31 | 4.42 | 0.22% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.76 | 6.59 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Bajaj Healthcare Ltd manufactures active pharmaceutical ingredients and formulations, focusing on amino acids and nutritional supplements for healthcare industries.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 223.22 | 233.04 | 329.18 | 371.14 | 416.54 | 663.89 | 681.33 | 647.39 | 482.11 | 521.72 | ||||||||||
Raw Materials | 128.77 | 131.50 | 215.43 | 245.33 | 268.32 | 377.19 | 409.91 | 393.84 | 264.43 | 476.16 | ||||||||||
Power & Fuel Cost | 14.12 | 16.79 | 19.81 | 21.83 | 24.24 | 24.96 | 31.83 | 37.69 | 31.47 | |||||||||||
Employee Cost | 16.93 | 19.57 | 21.65 | 24.62 | 28.18 | 34.55 | 41.11 | 42.32 | 43.85 | |||||||||||
Selling & Administrative Expenses | 6.01 | 5.68 | 5.68 | 7.31 | 8.00 | 12.91 | 14.86 | 14.86 | 16.21 | |||||||||||
Operating & Other expenses | 26.96 | 26.28 | 25.10 | 28.16 | 32.98 | 71.00 | 63.52 | 66.11 | 154.92 | |||||||||||
EBITDA | 30.43 | 33.22 | 41.51 | 43.89 | 54.82 | 143.28 | 120.10 | 92.57 | -28.77 | 45.56 | ||||||||||
Depreciation/Amortization | 9.29 | 11.35 | 11.08 | 11.41 | 12.12 | 16.12 | 17.64 | 17.21 | 27.62 | 28.19 | ||||||||||
PBIT | 21.14 | 21.87 | 30.43 | 32.48 | 42.70 | 127.16 | 102.46 | 75.36 | -56.39 | 17.37 | ||||||||||
Interest & Other Items | 7.64 | 8.20 | 7.73 | 8.32 | 6.63 | 8.34 | 12.78 | 17.68 | 29.75 | 28.98 | ||||||||||
PBT | 13.50 | 13.67 | 22.70 | 24.16 | 36.07 | 118.82 | 89.68 | 57.68 | -86.14 | -11.61 | ||||||||||
Taxes & Other Items | 5.29 | 5.87 | 7.50 | 7.86 | 10.82 | 35.71 | 18.30 | 14.65 | -2.35 | 3.91 | ||||||||||
Net Income | 8.21 | 7.80 | 15.20 | 16.30 | 25.25 | 83.11 | 71.38 | 43.03 | -83.79 | -15.52 | ||||||||||
EPS | 2.28 | 1.43 | 2.75 | 2.95 | 4.57 | 15.06 | 17.24 | 15.59 | -30.36 | -5.62 | ||||||||||
DPS | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 1.38 | 1.50 | 1.00 | 1.00 | 1.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.09 | 0.00 | 0.00 | 0.09 | 0.09 | 0.06 | — | -0.18 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Bajaj Healthcare Ltd | -14.69 | 4.42 | 0.22% |
Sun Pharmaceutical Industries Ltd | 45.10 | 6.44 | 0.75% |
Cipla Ltd | 30.06 | 4.62 | 0.85% |
Torrent Pharmaceuticals Ltd | 68.72 | 16.60 | 0.83% |
Price Comparison
Compare BAJAJHCARE with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 8.55%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.06%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.31%
Top 1 Mutual Funds holding Bajaj Healthcare Ltd
Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Pharma and Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0701% | Percentage of the fund’s portfolio invested in the stock 0.97% | Change in the portfolio weight of the stock over the last 3 months 0.97% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 28/37 (+9) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Dividend/Share
₹1.50
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 28, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Sep 28, 2021
Cash Dividend
Ex DateEx DateSep 28, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Sep 28, 2021
Revenue from operations jumped 31.5% YoY to Rs 133.08 crore in Q2 FY25. Profit before tax (PBT) surged 137.4% to Rs 12.44 crore in Q2 FY25 as compared with Rs 5.24 crore posted in same quarter last year. EBITDA stood at Rs 24.52 crore during the quarter, registering the growth 29.4% as compared with Rs 189.5 crore in Q2 FY24. EBITDA fell to 18.4% in Q2 FY25 as compared with 18.7% in Q2 FY24. In Q2 FY25, revenue from opium processing skyrocketed 582.9% YoY to Rs 13.66 crore, while API (domestic) and formulations jumped 21.8% and 27.7% YoY, respectively. API (exports) grew 12.3% YoY to Rs 29.20 crore. Anil Jain, managing director, Bajaj Healthcare, said, 'I am delighted to present the impressive results of our second quarter for FY25. Our revenue from operations surged by approximately 32% year-on-year led by robust performance across all segments ' this coupled with expansion in our margins resulted in a 90% year-on-year increase in our bottom line from our continuing operations We continue to undertake all efforts to sell the assets from the discontinued operations and to use the proceeds for further debt repayment and minimize the losses from the discontinued operations. We have materially repaid our borrowings to the tune of Rs 150.0 crore and this has further strengthened our financial position. Contribution from our API and Formulation segments rose, with both registering strong growth at 19% and 28%, respectively. The domestic demand has remained quite encouraging and has been a source of strength even as export markets are still largely wrestling sticky inflation and elevated freights. Another key highlight was the exceptional performance of our Opium Processing business, which grew multi-fold year-on-year. The segment has quickly become a meaningful growth driver for our overall business. We are focused on expanding capacity to meet increasing government requirements and sustain its high growth trajectory going forward. Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America. The counter rallied 7.75% to settle at Rs 390.75 on Thursday, 14 November 2024.Powered by Capital Market - Live
Net profit of Bajaj Healthcare reported to Rs 9.46 crore in the quarter ended September 2024 as against net loss of Rs 3.46 crore during the previous quarter ended September 2023. Sales rose 31.50% to Rs 133.09 crore in the quarter ended September 2024 as against Rs 101.21 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales133.09101.21 31 OPM %18.4218.71 - PBDT19.2511.90 62 PBT12.445.24 137 NP9.46-3.46 LP Powered by Capital Market - Live
Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Bajaj Healthcare has entered into a development and supply agreement for an Active Pharmaceutical Ingredient (API) with a European entity. This API after its development will be initially supplied in small quantities and will be used by the EU partner to carry out clinical trials for an alternative indication. Based on the outcome of these trials, the supplies will be done from the Company's FDA approved manufacturing facility situated at Savli, Vadodara.Powered by Capital Market - Live
After the development, the API will be initially supplied in small quantities and will be used by the EU partner to carry out clinical trials for an alternative indication. The trust reposed in the company by the EU partner for sourcing clinical trial quantities is a testimony of the company's development and manufacturing capabilities along with the good manufacturing practices (GMP) compliance at company's manufacturing units. Based on the outcome of these trials, the supplies will be done from the company's FDA approved manufacturing facility situated at Savli, Vadodara. Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations. It has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America. The company's standalone net profit jumped 14.1% to Rs 8.02 crore in Q1 FY25 as against 7.03 crore recorded in Q1 FY24. Revenue from operations increased 1.9% YoY to Rs 132.25 crore in Q1 FY25.Powered by Capital Market - Live
The Board of Bajaj Healthcare at its meeting held on 19 September 2024 has approved the allotment of 39,84,852 equity shares of the Company of face value of Rs. 5/- each fully paid at a price of Rs. 338/-, (including a premium of Rs. 333/- per equity share) aggregating to Rs. 1,34,68,79,976/-. The board has also approved allotment of 20,79,409 fully convertible warrants with each warrant convertible into or exchangeable for One (1) fully paid-up equity share of the Company of face value of Rs. 5/- each at an issue price of Rs. 338/-(including a premium of Rs. 333/-) per warrant, aggregating to Rs. 70,28,40,242/- to the Promoter, Promoter Group and Persons belonging to Non-Promoter category on Preferential Basis. Consequent to the aforesaid allotment of Equity Shares, the paid-up equity share capital of the Company stands increased to Rs. 15,79,16,260 comprising of 3,15,83,252 equity shares of the face value of Rs. 5/- each.Powered by Capital Market - Live
Bajaj Healthcare announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 19 September 2024.Powered by Capital Market - Live
Net profit of Bajaj Healthcare reported to Rs 7.13 crore in the quarter ended June 2024 as against net loss of Rs 48.21 crore during the previous quarter ended June 2023. Sales rose 1.93% to Rs 132.25 crore in the quarter ended June 2024 as against Rs 129.74 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales132.25129.74 2 OPM %18.5316.76 - PBDT16.9113.22 28 PBT10.186.91 47 NP7.13-48.21 LP Powered by Capital Market - Live
Bajaj Healthcare will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 5.37%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.17% to 0.13%